AEterna Zentaris - 48 Year Dividend History | AEZS

Historical dividend payout and yield for AEterna Zentaris (AEZS) since 1971. The current TTM dividend payout for AEterna Zentaris (AEZS) as of April 17, 2019 is $0.00. The current dividend yield for AEterna Zentaris as of April 17, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.071B $0.027B
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $112.392B 12.66
Gilead Sciences (GILD) United States $80.676B 10.27
Bio-Techne Corp (TECH) United States $7.127B 48.02